Академический Документы
Профессиональный Документы
Культура Документы
Management of neuroleptic
malignant syndrome
Neuroleptic malignant syndrome is a rare but serious adverse reaction resulting from antipsychotic
drug therapy. This article describes the signs and symptoms that pharmacists should look out for and
how this poorly understood syndrome should be managed. By Ewan Maule.
At a glance...
What is NMS?
A rare but serious adverse event related
to antipsychotic drugs.
What are the main symptoms?
Altered mental status, pyrexia, muscle
rigidity and autonomic dysfunction.
How common is it?
NMS occurs in 0.022.4% of patients
treated with antipsychotic drugs.
How is it managed?
Cessation of causative drug and
provision of supportive care.
Pharmacological interventions (such
as dantrolene and bromocriptine)
are commonly used, despite limited
evidence.
Can the causative drug be restarted?
Yes, but guidelines should be followed
to minimise the risk of relapse.
Diagnosis
Epidemiology
Pathogenesis
Copyright of the The British Journal of Clinical Pharmacy. No reproduction in any format is allowed unless permission is granted by the publisher
drug safety
Antipsychotic drugs
Antiemetic drugs
Other causes
Haloperidol (responsible
for 5060% cases)
Domperidone
Lithium
Thioridazine
Droperidol
CNS stimulants
Risperidone
Metoclopramide
Amphetamines
Quetiapine
Prochlorperazine
Cocaine
Perphenazine
Promethazine
Overdose of tricyclic
antidepressants
Paliperidone
Withdrawal of amantadine
Clozapine
Chlorpromazine
Withdrawal of
bromocriptine
Aripiprazole
Withdrawal of levodopa
Pharmacological management of
hypertension, if applicable
Administration of low molecular
weight heparin to prevent venous
thromboembolism
Clinical symptoms
Altered mental status: drowsiness and confusion, progressing to stupor and coma
Pyrexia: temperature typically over 38C
Autonomic dysfunction: usually tachycardia or labile blood pressure
Muscle rigidity: often described as lead pipe rigidity
Tachypnea (rapid breathing)
Diaphoresis (excessive sweating)
Drooling
Incontinence
Biochemical symptoms
Raised creatine kinase: usually in excess of 1,000 IU/L. Levels up to 100,000 IU/L have
been reported3
Leucocytosis: present in up to 75% of cases3
Iron deficiency
Liver function abnormalities
Figure 2. Symptoms associated with neuroleptic malignant syndrome
The British Journal of Clinical Pharmacy Vol.1 July/August 2009
Copyright of the The British Journal of Clinical Pharmacy. No reproduction in any format is allowed unless permission is granted by the publisher
drug safety
Serotonin syndrome
Malignant hyperthermia
Differential diagnosis
Baclofen withdrawal
Environmental heat stroke
Alcohol or sedative withdrawal
Lithium or monoamine oxidase inhibitor
overdose/toxicity
Conclusions
205
Copyright of the The British Journal of Clinical Pharmacy. No reproduction in any format is allowed unless permission is granted by the publisher